🌍 Global Peptide Market Overview (2024-2030)¶
Report ID: MKI-GM-2026-001 | Release Date: July 2026
Data Cutoff: 2026 Q2 | Coverage: Global peptide drugs, cosmetic peptides, food peptide market
1. Market Size and Growth Trajectory¶
The global peptide market has maintained steady high growth over the past five years, surpassing $45B in 2024, with GLP-1 drugs contributing the majority of incremental growth. The market is expected to reach $78B by 2030, with a 2024-2030 CAGR of approximately 9.5%.
1.1 Global Peptide Market Historical Size¶
| Year | Market Size ($B) | YoY Growth | Notes |
|---|---|---|---|
| 2020 | $32.4 | — | COVID-19 impacted some clinical timelines |
| 2021 | $34.8 | +7.4% | GLP-1 prescription volume resumed growth |
| 2022 | $37.6 | +8.0% | Semaglutide volume accelerated |
| 2023 | $41.5 | +10.4% | Tirzepatide approved for obesity indication |
| 2024 | $45.2 | +8.9% | Oral semaglutide rapid growth |
| 2025E | $49.8 | +10.2% | Mazdutide expected China approval |
| 2026E | $55.0 | +10.4% | Multi-target agonists launching intensively |
| 2028E | $65.0 | — | GLP-1 generics entering market |
| 2030E | $78.0 | — | Oral formulations account for 30% of therapeutic peptides |
Market Inflection Point Assessment
2025-2027 will see a dual inflection point of "GLP-1 generic drug launches + multi-target new drug intensive approvals," with market growth potentially briefly exceeding 12%. Post-2030, growth will moderate to 6-8%.
2. End-Use Application Segmentation¶
2.1 Peptide Market End-Use Composition (2024)¶
| End-Use Category | Market Size ($B) | Share | Leading Products | Growth (YoY) |
|---|---|---|---|---|
| Therapeutic Peptide Drugs | $35.3 | 78% | GLP-1 class, anti-tumor peptides, antimicrobial peptides | +10.2% |
| Cosmetic Peptides | $5.4 | 12% | Copper peptide, Acetyl Hexapeptide-8, Palmitoyl Pentapeptide | +14.5% |
| Functional Food Peptides | $4.5 | 10% | Collagen peptides, soy peptides, corn peptides | +8.3% |
2.2 Therapeutic Peptide Breakdown ($35.3B Detail)¶
| Sub-Segment | Market Size ($B) | Share of Therapeutic | Representative Products |
|---|---|---|---|
| GLP-1 Receptor Agonists | $24.9 | 70.5% | Semaglutide, Tirzepatide, Dulaglutide |
| Anti-Tumor Peptides | $3.8 | 10.8% | Leuprolide, Goserelin, PDC drugs |
| Antimicrobial/Antiviral Peptides | $1.5 | 4.2% | Polymyxins, Daptomycin |
| Other Metabolic Peptides | $3.2 | 9.1% | Insulin analogs, PTH analogs |
| Other (including rare disease) | $1.9 | 5.4% | Somatostatin analogs, GnRH antagonists |
3. Regional Market Analysis¶
3.1 Regional Market Share and Growth Characteristics¶
| Region | 2024 Market Share | 2030E Market Share | CAGR (24-30) | Core Characteristics |
|---|---|---|---|---|
| North America | 45% | 42% | 8.5% | Primary innovative drug market, highest GLP-1 penetration |
| Europe | 25% | 23% | 7.8% | Intense generic competition, highest regulatory standards |
| Asia-Pacific | 22% | 26% | 11.5% | China API capacity + Japan innovation + India generics |
| Middle East/Africa | 4% | 5% | 12.0% | Fast-growing emerging generic market |
| Latin America | 4% | 4% | 9.0% | Potential GLP-1 generic market |
3.2 Key Regional Market Characteristics¶
North America (2024: ~$20.3B) - US accounts for over 90% of North America - Semaglutide (Ozempic + Wegovy + Rybelsus) combined sales of $21.2B in 2024 - Tirzepatide (Mounjaro + Zepbound) sales of $11.5B in 2024 - Obesity drug prescription volume growing over 40% annually
Europe (2024: ~$11.3B) - Germany, UK, France are the top three markets - EMA accelerating peptide generic drug approvals - 2026-2027 GLP-1 biosimilars expected to enter European market intensively
China Market (2024: ~$5.4B / ¥38B) - China therapeutic peptide drug market size approximately ¥38B (2024) - API exports $1.8B, global share 38% - Domestic GLP-1 drugs (Innovent Mazdutide, Hengrui Noliglipin) expected to be approved in 2025-2026
4. Growth Driver Analysis¶
4.1 GLP-1 Market Explosion (Core Driver)¶
GLP-1 receptor agonists are the most important growth driver of the peptide market:
| Factor | Impact Level | Description |
|---|---|---|
| Indication Expansion | ★★★★★ | T2D → Obesity → CVD → MASH → CKD → AD, market space continuously expanding |
| Oral Formulation Breakthrough | ★★★★☆ | Oral semaglutide 2024 sales $2.86B, driving oral peptide R&D |
| Multi-Target Innovation | ★★★★☆ | GIP/GLP-1 dual-target, GCG/GLP-1 dual-target, triple-target new drugs |
| China Demand Explosion | ★★★★☆ | China obese population exceeds 180 million, GLP-1 prescriptions growing 50%+ annually |
4.2 Other Growth Drivers¶
- Population Aging: Global 65+ population share rising from 9.3% in 2020 to 11.7% by 2030, driving rigid demand for chronic disease medications
- Increased R&D Investment: Global peptide drug R&D pipeline grew from approximately 1,200 in 2020 to 2,100 in 2024
- Synthesis Technology Innovation: Solid-phase synthesis (SPPS) efficiency improved 10x, liquid-phase synthesis (LPPS) continuous production reducing costs
- CDMO Capability Enhancement: Global peptide CDMO market reached $3.2B in 2024, China CDMO share rising to 32%
5. Competitive Landscape Overview¶
5.1 Market Concentration (2024)¶
| Rank | Company | Peptide Revenue ($B) | Market Share | Core Products |
|---|---|---|---|---|
| 1 | Novo Nordisk | $26.0 | 57.5% | Semaglutide series |
| 2 | Eli Lilly | $13.5 | 29.9% | Tirzepatide, Dulaglutide |
| 3 | Pfizer | $1.2 | 2.7% | Various innovative peptides |
| 4 | AstraZeneca | $0.9 | 2.0% | Endocrine peptides |
| 5 | Others (incl. China CDMO) | $3.6 | 7.9% | — |
Concentration Risk
Novo Nordisk and Eli Lilly together account for 87.4% of the peptide drug market. This high concentration is expected to gradually decrease after GLP-1 patent expirations. By 2030, the combined share of the two giants is expected to decline to 60-65%.
6. Future Trends and Outlook (2025-2030)¶
6.1 Key Trends¶
- Oral Peptide Revolution: Oral GLP-1 drug market expected to reach $35B+ by 2026, oral formulations to account for 30% of therapeutic peptides by 2030
- Multi-Target Era: GIP/GLP-1/GCG triple agonists (e.g., Retatrutide) expected to become next-generation blockbusters
- Generic Drug Wave: 2026-2028 global GLP-1 generic drugs launching intensively, price decline 30-50%, market shifting to volume-for-value
- Chinese Innovation Going Global: Innovative peptide drugs from Chinese companies (Innovent, Hengrui) expected to enter global markets
- Intelligent Manufacturing: AI-driven peptide sequence design and continuous flow synthesis technology will significantly reduce production costs
6.2 Market Size Forecast¶
| Year | Global Market ($B) | GLP-1 Share | China Share | China CDMO Global Share |
|---|---|---|---|---|
| 2024 | $45.2 | 55% | 12% | 32% |
| 2025E | $49.8 | 58% | 13% | 35% |
| 2026E | $55.0 | 60% | 14% | 38% |
| 2028E | $65.0 | 55% | 16% | 42% |
| 2030E | $78.0 | 50% | 18% | 45% |
Conclusion¶
The global peptide market is in a super-growth cycle driven by GLP-1. The period 2024-2030 will see a complete cycle evolution of "innovative drug explosion → generics entering → multi-player competition." Benefiting from API capacity advantages and CDMO service capability improvements, China's position in the global peptide industry chain will continue to strengthen. For industry participants, capturing GLP-1 industry chain opportunities, deploying multi-target innovative drugs, and building differentiated CDMO service capabilities will be the core strategic directions for the next five years.
Data Sources and Disclaimer
This report compiles data from Frost & Sullivan, Grand View Research, Evaluate Pharma, company annual reports, the China Pharmaceutical Industry Information Center, and Yaozhi.com among other public channels. Market estimate data may have statistical methodology differences and is for reference only.
SENO Biotechnology — Professional Peptide API and CDMO Service Provider. For semaglutide, tirzepatide, cosmetic peptide API pricing, or custom synthesis CDMO services, please visit SENO Biotechnology Manufacturing Capabilities for detailed information.